Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 2
Submit an article Journal homepage
532
Views
12
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma

Kevin HayDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada
,
Benny LeeFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada
,
Ozge GoktepeCancer Surveillance & Outcomes, British Columbia Cancer Agency, Vancouver, BC, Canada
,
Joseph M. ConnorsDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
,
Laurie H. SehnDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
,
Kerry J. SavageDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
,
Richard KlasaDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
,
Tamara ShenkierDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
,
Alina GerrieDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada;Leukemia/Bone Marrow Transplantation Program of BC, Vancouver, BC, Canada
&
Diego VillaDivision of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, CanadaCorrespondence[email protected]
 show all
Pages 276-282 | Received 24 Feb 2015, Accepted 22 May 2015, Published online: 19 Jun 2015

References

  • Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684–1692.
  • Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004;2004(1):221–236.
  • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
  • Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
  • Habermann TM, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
  • Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–22.
  • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
  • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
  • National Institute for Clinical Excellence. Improving outcomes in haematological cancers. London: NICE; 2003.
  • Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31: 3061–3068.
  • Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24:4888–4894.
  • Gagliato D de M, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 2014;32:735–744.
  • BC Stats. 2006 Neighbourhood Income and Demographics. 2008. Available at: http://www.bcstats.gov.bc.ca/statisticsbysubject/LabourIncome/OtherData/IncomeTaxation.aspx. Accessed July 29, 2013.
  • Statistics Canada. Postal Code Conversion File (PCCF). 2013. Available at: http://www5.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno = 92F0153XCE&lang = eng. Accessed July 29, 2013.
  • Du Plessis V, Beshiri R, Bollman R, et al. Definitions of “Rural.” Agric Rural Work Pap Ser Stat Canada, Agric Div. 2002. Available at: http://ageconsearch.umn.edu/bitstream/28031/1/wp020061.pdf. Accessed July 29, 2013.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481. doi:10.2307/2281868
  • Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281–1288.
  • Ferreri AJM. How I treat primary CNS lymphoma. Blood. 2011;118:510–522.
  • Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009;113:28–36.
  • Wahl SK, Gildengorin G, Feusner J. Weekend delay in initiation of chemotherapy for acute lymphoblastic leukemia: does it matter? J Pediatr Hematol Oncol 2012;34:e8–e11.
  • Nurgalieva ZZ, Franzini L, Morgan RO, et al. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 2013;30:419.
  • Yu K-D, Huang S, Zhang J-X, et al. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:240.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.